Tag: lacutamab
Innate Pharma: ASH 2023, presentation of new clinical data for Lacutamab and SAR443579/IPH6101
By Hector Chaunu Published on 03/11/2023 at 08:22 a.m. (Boursier.com) — Innate Pharma SA announces that the following…
Innate Pharma: Data presented on lacutamab at ASH – 12/12/2022 at 10:08
(CercleFinance.com) – Innate Pharma reports that it has presented data from a preliminary analysis of the Phase II Tellomak trial demonstrating clinical activity and a favorable safety profile for lacutamab,…
Innate Pharma: clinical activity and favorable safety profile of lacutamab – 09/23/2022 at 08:54
(AOF) – Innate Pharma announced that its anti-KIR3DL2 antibody, lacutamab, has established clinical responses in patients with mycosis fungoides in the Phase 2 Tellomak trial. “Therapeutic options are limited for…